Compare IZM & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZM | SBFM |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | China | United States |
| Employees | N/A | 50 |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0M | 4.9M |
| IPO Year | 2021 | N/A |
| Metric | IZM | SBFM |
|---|---|---|
| Price | $0.40 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 163.3K | 30.3K |
| Earning Date | 10-24-2025 | 04-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $40.47 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.95 |
| 52 Week High | $2.74 | $2.43 |
| Indicator | IZM | SBFM |
|---|---|---|
| Relative Strength Index (RSI) | 43.21 | 55.22 |
| Support Level | $0.37 | $1.05 |
| Resistance Level | $0.99 | $1.24 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 48.39 | 91.83 |
ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.